Murphy SC, et al. - Researchers performed a double-blind, randomized, placebo-controlled trial to assess safety, tolerability, pharmacokinetics and efficacy of one oral dose of 400 mg DSM265 pre-controlled human malarial infection (CHMI). It was noticed that DSM265 given three or seven days before CHMI was safe and well-tolerated but sterilely protected only one-third of participants.